TBI-166
TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine[2][3].
Product Specifications
CAS Number
1353734-12-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/tbi-166.html
Purity
98.19
Solubility
DMSO : 9.09 mg/mL (ultrasonic; adjust pH to 3 with HCl)
Smiles
FC(F)(F)OC1=CC=C(N2C3=C/C(C(NC4=CC=CN=C4OC)=CC3=NC5=C2C=CC=C5)=N/C6CCC(OC)CC6)C=C1
Molecular Formula
C32H30F3N5O3
Molecular Weight
589.61
Precautions
H302, H315, H319
References & Citations
[1]Xu J, et al. In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63 (5) :e02155-18. |[2]Zhu H, et al. Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models. Antimicrob Agents Chemother. 2021 Mar 18;65 (4) :e02164-20. |[3]Ding Y, et al. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. Antimicrob Agents Chemother. 2022 Sep 20;66 (9) :e0065822.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
R15309h 1 Each
Human POU2F3 / POU domain, class 2, transcription factor 3 Recombinant Protein
Sign In for Pricing
View Details 